2nd Mar 2016 09:44
LONDON (Alliance News) - Evgen Pharma PLC said Wednesday that it has received the approvals it needs to begin a phase II trial of its drug SFX-01 in aneurysmal subarachnoid haemorrhage, a form of stroke.
Patient recruitment and first dosing in a 90 patient trial is expected to start early in the second quarter of 2016.
"We are pleased to have received the required approvals to commence this Phase II trial of our novel compound SFX-01 in aneurysmal subarachnoid haemorrhage. There is a very clear unmet medical need in this condition, for which there has been no significant clinical advances for more than 20 years," said Chief Executive Officer Stephen Franklin in a statement.
"I am also pleased to report that the company's other programmes in metastatic breast cancer and multiple sclerosis are proceeding as planned and we will provide updates on these programmes in due course," Franklin added.
Shares in Evgen were untraded Wednesday morning, having last traded at 19.50 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L